CAR T Cell Therapies for ALL and NHL
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
Clinical Pearls
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
- A phase I study will be presented at ASH evaluating CAR T cell therapy directed against CD19 for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
- Another phase I study evaluated high dose therapy and ASCT followed by CAR T cell therapy directed against CD19 for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Evaluating Role of Loncastuximab in Third-Line DLBCL After CAR T
May 7th 2025During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.
Read More
Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery
April 30th 2025Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.
Read More
